High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib (AG-120) and Azacitidine

Scott R. Daigle; Sung Choe; Lynn Quek; Courtney D. DiNardo; Anthony Stein; Eytan M. Stein; Amir T. Fathi; Olga Frankfurt; Andre C. Schuh; Hagop M. Kantarjian; Vickie Zhang; Thomas Winkler; Paresh Vyas; Bin Wu

doi:10.1182/blood-2019-122590

High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib (AG-120) and Azacitidine

Scott R. Daigle, Sung Choe, Lynn Quek, Courtney D. DiNardo, Anthony Stein, Eytan M. Stein, Amir T. Fathi, Olga Frankfurt, Andre C. Schuh, Hagop M. Kantarjian, Vickie Zhang, Thomas Winkler, Paresh Vyas, Bin Wu

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Journal	Blood
Volume	134
DOIs	https://doi.org/10.1182/blood-2019-122590
Publication status	Published - 13 Nov 2019

Access to Document

10.1182/blood-2019-122590

Cite this

Daigle, S. R., Choe, S., Quek, L., DiNardo, C. D., Stein, A., Stein, E. M., Fathi, A. T., Frankfurt, O., Schuh, A. C., Kantarjian, H. M., Zhang, V., Winkler, T., Vyas, P., & Wu, B. (2019). High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib (AG-120) and Azacitidine. Blood, 134. https://doi.org/10.1182/blood-2019-122590

@article{57253250ac624cb2a8b12c8f7148e3c9,

title = "High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib (AG-120) and Azacitidine",

author = "Daigle, {Scott R.} and Sung Choe and Lynn Quek and DiNardo, {Courtney D.} and Anthony Stein and Stein, {Eytan M.} and Fathi, {Amir T.} and Olga Frankfurt and Schuh, {Andre C.} and Kantarjian, {Hagop M.} and Vickie Zhang and Thomas Winkler and Paresh Vyas and Bin Wu",

year = "2019",

month = nov,

day = "13",

doi = "10.1182/blood-2019-122590",

language = "English",

volume = "134",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

}

Daigle, SR, Choe, S, Quek, L, DiNardo, CD, Stein, A, Stein, EM, Fathi, AT, Frankfurt, O, Schuh, AC, Kantarjian, HM, Zhang, V, Winkler, T, Vyas, P & Wu, B 2019, 'High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib (AG-120) and Azacitidine', Blood, vol. 134. https://doi.org/10.1182/blood-2019-122590

TY - JOUR

T1 - High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib (AG-120) and Azacitidine

AU - Daigle, Scott R.

AU - Choe, Sung

AU - Quek, Lynn

AU - DiNardo, Courtney D.

AU - Stein, Anthony

AU - Stein, Eytan M.

AU - Fathi, Amir T.

AU - Frankfurt, Olga

AU - Schuh, Andre C.

AU - Kantarjian, Hagop M.

AU - Zhang, Vickie

AU - Winkler, Thomas

AU - Vyas, Paresh

AU - Wu, Bin

PY - 2019/11/13

Y1 - 2019/11/13

U2 - 10.1182/blood-2019-122590

DO - 10.1182/blood-2019-122590

M3 - Meeting Abstract

SN - 0006-4971

VL - 134

JO - Blood

JF - Blood

ER -